Recent Updates
Recently added Catalysts
ZYME

Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology

Monday, January 8, 2018 1 min read
Key Takeaway: Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology

Full Press Release Details

Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology.
Tags: ZYME Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 8, 2018